Matthew Durdy, a former investment banker and biotech executive, has been promoted to the position of chief executive of the UK Cell and Gene Therapy Catapult, effective April, to succeed Keith Thompson who is retiring. Mr Durdy is currently the Catapult’s chief business officer and has helped pioneer the business model for the Catapult’s manufacturing centre. Mr Durdy holds an MA in pure and applied biology from the University of Oxford, UK and an MBA from the University of Chicago, US.
The Catapult announced the appointment on 29 January 2020.
Copyright 2020 Evernow Publishing Ltd